Format

Send to

Choose Destination
Cell Commun Signal. 2017 Oct 10;15(1):41. doi: 10.1186/s12964-017-0195-9.

DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway.

Author information

1
Cold Spring Harbor Laboratory, New York, USA. bhattacharjee@cshl.edu.
2
Cold Spring Harbor Laboratory, New York, USA. snandi@cshl.edu.

Abstract

Fanconi Anemia (FA) is a rare, inherited genomic instability disorder, caused by mutations in genes involved in the repair of interstrand DNA crosslinks (ICLs). The FA signaling network contains a unique nuclear protein complex that mediates the monoubiquitylation of the FANCD2 and FANCI heterodimer, and coordinates activities of the downstream DNA repair pathway including nucleotide excision repair, translesion synthesis, and homologous recombination. FA proteins act at different steps of ICL repair in sensing, recognition and processing of DNA lesions. The multi-protein network is tightly regulated by complex mechanisms, such as ubiquitination, phosphorylation, and degradation signals that are critical for the maintenance of genome integrity and suppressing tumorigenesis. Here, we discuss recent advances in our understanding of how the FA proteins participate in ICL repair and regulation of the FA signaling network that assures the safeguard of the genome. We further discuss the potential application of designing small molecule inhibitors that inhibit the FA pathway and are synthetic lethal with DNA repair enzymes that can be used for cancer therapeutics.

KEYWORDS:

Cancer therapeutics; Combination Therapy Genomic instability; DNA damage response; DNA repair; Fanconi Anemia (FA) signaling network; Homologous recombination; Interstrand crosslink (ICL); Synthetic lethality; Translesion synthesis

PMID:
29017571
PMCID:
PMC5635482
DOI:
10.1186/s12964-017-0195-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center